OverviewSuggest Edit
The UK’s first dedicated synthetic biology company with a world leading platform of technologies for the rapid engineering and optimisation of novel biological production systems. A spin out of University College London, Synthace is already producing high-value research and development products for the pharmaceutical, agrochemical and fine chemicals industry. Synthace bioengineering is enabled by a tight integration of computational modelling and big data analysis with wet lab experimental design and validation, and novel molecular biology tools. While Synthace bioengineering is broadly applicable across multiple industry sectors, the company is focused towards applications in the production of specialty chemicals.
| Type | Private | |
| Founded | 2011 | |
| HQ | London, GB | Map |
| Website | synthace.com |
Key People/Management at Synthace
Bob Wiederhold
Chairman
Tim Fell
Chief Executive Officer, Director
Christopher Grant Ward
Co-Founder
Susan Shiff
Non-Executive Director
Isabel Fox
Non-Executive Director
Patrick Zhang
Non-Executive Director
Synthace Office Locations
Synthace has offices in London and Cambridge
London, GB (HQ)
195 Wood Ln, Shepherd's Bush
Cambridge, MA, US
101 Main St
Synthace Financials and Metrics
Summary Metrics
Founding Date | 2011 |
Synthace total Funding | $41.8 m |
Synthace latest funding size | $25.6 m |
Time since last funding | 3 years ago |
Synthace investors | Horizons Ventures, Amadeus Capital Partners, Sofinnova Partners, Rainbow Seed Fund, David Lucas, John Anthony Knight, Keith Willey, Michail Eleftheriou, Sami Mikati, Sharaf Yamani, SOSV, White Cloud Capital, Eleven Two Capital, Bioeconomy Capital, Luminous Ventures, Patrick Zhang |
Synthace's latest funding round in December 2018 was reported to be $25.6 m. In total, Synthace has raised $41.8 m
Synthace Revenue
Synthace's revenue was reported to be £581 in FY, 2013
| GBP | |
|---|---|
Revenue (FY, 2013) | 581.0 |
Net income (FY, 2013) | (361.6k) |
EBITDA (FY, 2013) | (356.8k) |
EBIT (FY, 2013) | (361.6k) |
Cash (31-May-2018) | 4.9m |
| GBP | FY, 2012 | FY, 2013 |
|---|---|---|
Revenue | 581.0 | |
Operating expense total | 362.2k | |
EBITDA | (356.8k) | |
EBITDA margin, % | (61413%) |
| GBP | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|---|
Cash | 351.4k | 103.4k | 321.7k | 1.5m | 245.0k | 224.3k | 4.9m |
Accounts Receivable | 240.0 | 159.9k | 73.2k | 9.6k | 46.6k | 107.7k | |
Current Assets | 358.1k | 150.1k | 481.6k | 1.6m | 646.8k | 883.2k | 5.8m |
PP&E | 1.6k | 14.8k | 298.8k | 200.5k | 265.6k | 186.8k | 235.7k |
| GBP | FY, 2012 | FY, 2013 |
|---|---|---|
Net Income | (43.1k) | (361.6k) |
| GBP | FY, 2012 |
|---|---|
Financial Leverage | 1 x |
Synthace Cybersecurity Score
Synthace Online and Social Media Presence
1.63k Twitter followers
Synthace has 1.63k Twitter Followers. The number of followers has increased 0.3% month over month and increased 2.3% quarter over quarter
Synthace's Trends
Twitter Engagement Stats for @synthace
1.4k
Tweets
184
Following
1.6k
Followers
31
Tweets last 30 days
1.7
Avg. likes per Tweet
87.1%
Tweets with engagement
Synthace News and Updates
December 12, 2018
Synthace raises $25.6 million to automate bio labs with software
Synthace, a U.K. startup developing an operating system to automate lab work, announced that it has raised $25.6 million in a Series B round.
September 19, 2017
Synthace reels in $9.6 mln Series A
London-based Synthace, the developer of the Antha operating system for biology, has raised $9.6 million in Series A funding. The investors included White Cloud Capital, Amadeus Capital Partners, Eleven Two Capital, Sofinnova Partners, SOSV and Bioeconomy Capital.
Synthace Blogs
May 28, 2021
Designing for Biotech: Insights in Product Design (Part 1)
Designing for Biotech: Insights in Product Design (Part 1) Filter Search by keyword Browse by category Article Bioprocessing Gene Therapy Lab of the Future News Our People Tags AI Bioprocessing Conference Customer Success Data Demo Design of Experiments (DOE) DNA Assembly ELISA Engineering Gene Ther…
May 24, 2021
Rapid Automation and Analysis of a Competitive ELISA Kit with Antha
Rapid Automation and Analysis of a Competitive ELISA Kit with Antha Read the full report × Key findings.... Rapid adaptation of an automated sandwich ELISA protocol to a competitive format in 15 min using our Antha® software. Antha integrated three independent devices into a single automated workcel…
May 19, 2021
Veteran Technology Executive Joins Synthace to Accelerate Its Mission to Revolutionize the Life Science Research Market
Veteran Technology Executive Joins Synthace to Accelerate Its Mission to Revolutionize the Life Science Research Market Filter Search by keyword Browse by category Article Bioprocessing Gene Therapy Lab of the Future News Our People Tags AI Bioprocessing Conference Customer Success Data Demo Design …
May 11, 2021
Enhance Your Optimizations with Flexible, Automated Design of Experiments (DOE)
Enhance Your Optimizations with Flexible, Automated Design of Experiments (DOE) Design of Experiments (DOE) is a powerful statistical approach to exploring the design space and optimizing experiments. In biology, its usage is facilitated by technique familiarity and statistical experience, but also …
April 11, 2021
People of Synthace: Sarah James, PhD – Senior Technical Specialist
People of Synthace: Sarah James, PhD – Senior Technical Specialist Filter Search by keyword Browse by category Article Bioprocessing Gene Therapy Lab of the Future News Our People Tags AI Bioprocessing Conference Customer Success Data Demo Design of Experiments (DOE) DNA Assembly ELISA Engineering G…
March 29, 2021
People of Synthace: Matthew Gregg – Software Developer
People of Synthace: Matthew Gregg – Software Developer Filter Search by keyword Browse by category Article Bioprocessing Gene Therapy Lab of the Future News Our People Tags AI Bioprocessing Conference Customer Success Data Demo Design of Experiments (DOE) DNA Assembly ELISA Engineering Gene Therapy …
Synthace Frequently Asked Questions
When was Synthace founded?
Synthace was founded in 2011.
Who are Synthace key executives?
Synthace's key executives are Bob Wiederhold, Tim Fell and Christopher Grant Ward.
How many employees does Synthace have?
Synthace has 76 employees.
What is Synthace revenue?
Latest Synthace annual revenue is £581.
What is Synthace revenue per employee?
Latest Synthace revenue per employee is £8.
Who are Synthace competitors?
Competitors of Synthace include International Stem Cell Corporation, IDEX Health & Science and The Biomedical Engineering Society.
Where is Synthace headquarters?
Synthace headquarters is located at 195 Wood Ln, Shepherd's Bush, London.
Where are Synthace offices?
Synthace has offices in London and Cambridge.
How many offices does Synthace have?
Synthace has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies